Heron Therapeutics (HRTX) Other Non-Current Assets (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Other Non-Current Assets came in at $5.2 million in Q1 2026, down 17.13% YoY from $6.3 million in Q1 2025, and down 3.72% on a QoQ basis from $5.4 million in Q4 2025.
Heron Therapeutics (HRTX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Other Non-Current Assets data on file, last reported at $5.2 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 17.13% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 17.13% YoY) and the FY2025 annual result came in at $5.4 million, down 16.58% from the prior year.
- Other Non-Current Assets slipped to $5.2 million in Q1 2026, from $5.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $18.0 million in Q1 2022 to a low of $5.2 million in Q1 2026.
- A 5-year average of $9.7 million and a median of $7.9 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 5095.66% — and 2023, when it sank 51.71%.
- Tracing HRTX's Other Non-Current Assets over 5 years: stood at $15.7 million in 2022, then tumbled by 48.27% to $8.1 million in 2023, then retreated by 20.24% to $6.5 million in 2024, then fell by 16.58% to $5.4 million in 2025, then decreased by 3.72% to $5.2 million in 2026.
- The last three Other Non-Current Assets figures came in at $5.2 million (Q1 2026), $5.4 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn | 5.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.01 Mn |
| Mar 31, 2026 | 5.21 Mn |
| Dec 31, 2025 | 5.41 Mn |
| Sep 30, 2025 | 5.88 Mn |
| Jun 30, 2025 | 6.08 Mn |
| Mar 31, 2025 | 6.28 Mn |
| Dec 31, 2024 | 6.48 Mn |
| Sep 30, 2024 | 6.71 Mn |
| Jun 30, 2024 | 6.93 Mn |
| Mar 31, 2024 | 7.88 Mn |
| Dec 31, 2023 | 8.13 Mn |
| Sep 30, 2023 | 8.37 Mn |
| Jun 30, 2023 | 8.58 Mn |
| Mar 31, 2023 | 14.14 Mn |
| Dec 31, 2022 | 15.71 Mn |
| Sep 30, 2022 | 17.33 Mn |
| Jun 30, 2022 | 17.53 Mn |
| Mar 31, 2022 | 17.98 Mn |
| Dec 31, 2021 | 17.72 Mn |
| Sep 30, 2021 | 346,000.00 |